Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes

GAD-alum given into lymph nodes to type 1 diabetes patients participating in an open-label pilot trial resulted in preservation of C-peptide similar to promising results from other trials. Here, we compared the immunomodulatory effect of giving GAD-alum directly into lymph nodes versus that induced...

Descripción completa

Detalles Bibliográficos
Autores principales: Tavira, Beatriz, Barcenilla, Hugo, Wahlberg, Jeannette, Achenbach, Peter, Ludvigsson, Johnny, Casas, Rosaura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994289/
https://www.ncbi.nlm.nih.gov/pubmed/30009185
http://dx.doi.org/10.1155/2018/9391845

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994289/
https://www.ncbi.nlm.nih.gov/pubmed/30009185
http://dx.doi.org/10.1155/2018/9391845

Ejemplares similares